Basic Information
Twynsta Tablet 80mg/5mg
TABLET
Regulatory Information
SIN14010P
September 9, 2011
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XC09DB04
Company Information
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
BOEHRINGER INGELHEIM SINGAPORE PTE. LTD.
Active Ingredients
Strength: 80.000 mg
Strength: 5 mg
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity to the active substances, or to any of the excipients. - Hypersensitivity to dihydropyridine derivatives - Second and third trimesters of pregnancy - Lactation - Biliary obstructive disorders - Severe hepatic impairment - Severe hypotension - Shock (including cardiogenic shock) - Obstruction of the outflow tract of the left ventricle (e.g. high grade aortic stenosis) - Haemodynamically unstable heart failure after acute myocardial infarction - The concomitant use of TWYNSTA with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) In case of rare hereditary conditions that may be incompatible with an excipient of the product (see section List of excipients – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_), the use of the product is contraindicated.
Indication Information
**4.1 Indications** Treatment of essential hypertension. Replacement Therapy Patients receiving telmisartan and amlodipine from separate tablets may instead receive TWYNSTA containing the same component doses. Add on therapy TWYNSTA is indicated in patients whose blood pressure is not adequately controlled on telmisartan or amlodipine monotherapy. Initial therapy TWYNSTA may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of TWYNSTA as initial therapy for hypertension should be based on an assessment of potential benefits and risks.